Xiangdong Cheng
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer (NCT07068516) | Xiangdong Cheng | 2025-07-20 |
| QL1706 Combined With SOX Used in Theperioperative Treatment (NCT06766305) | Xiangdong Cheng | 2025-03-21 |
| Study of IBI363 in Patients with Advanced First-line Gastric Cancer (NCT06610799) | Xiangdong Cheng | 2024-10-15 |
| A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established (NCT06614179) | Xiangdong Cheng | 2024-07-01 |
| Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. (NCT06374901) | Xiangdong Cheng | 2024-04-25 |
| Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer. (NCT06642857) | Xiangdong Cheng | 2024-03-25 |
| Nivolumab Combined With SOX Used in the Perioperative Treatment (NCT05739045) | Xiangdong Cheng | 2022-11-03 |
Track Xiangdong Cheng automatically
Every clearance here is in the API, with alerts when new ones post.